Willebrand

Results: 314



#Item
1en77  Original Article Improved Handling of Synonymous SNOMED CT Concepts used in HL7 Version 3 by the Example of the Von Willebrand Disease

en77 Original Article Improved Handling of Synonymous SNOMED CT Concepts used in HL7 Version 3 by the Example of the Von Willebrand Disease

Add to Reading List

Source URL: www.ejbi.org

Language: English - Date: 2017-06-28 11:48:09
    2Supplementary Materials  Supplementary Figure 1. Ternary von Willebrand Factor A1-glycoprotein Ibalpha-botrocetin complex (PDB code: 1U0N) as an example of a non-interacting protein pair. Red – Von Willebrand factor (1

    Supplementary Materials Supplementary Figure 1. Ternary von Willebrand Factor A1-glycoprotein Ibalpha-botrocetin complex (PDB code: 1U0N) as an example of a non-interacting protein pair. Red – Von Willebrand factor (1

    Add to Reading List

    Source URL: mips.helmholtz-muenchen.de

    Language: English - Date: 2013-10-04 12:05:00
      3Article  pH-Dependent Interactions in Dimers Govern the Mechanics and Structure of von Willebrand Factor Jochen P. Mu¨ller,1,* Achim Lo¨f,1 Salome´ Mielke,1 Tobias Obser,2 Linda K. Bruetzel,1 Willem Vanderlinden,1,3 J

      Article pH-Dependent Interactions in Dimers Govern the Mechanics and Structure of von Willebrand Factor Jochen P. Mu¨ller,1,* Achim Lo¨f,1 Salome´ Mielke,1 Tobias Obser,2 Linda K. Bruetzel,1 Willem Vanderlinden,1,3 J

      Add to Reading List

      Source URL: www.biophysik.physik.uni-muenchen.de

      Language: English - Date: 2016-07-28 04:23:33
      4News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

      News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

      Add to Reading List

      Source URL: www.cslbehring.at

      Language: English - Date: 2013-11-18 05:52:30
      5News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

      News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

      Add to Reading List

      Source URL: www.cslbehring.at

      Language: English - Date: 2013-11-18 05:52:29
      6IP Internship project 7: Detailed characterisation of the molecular interaction between complement factor H (FH) and von Willebrand factor (VWF) Description Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic

      IP Internship project 7: Detailed characterisation of the molecular interaction between complement factor H (FH) and von Willebrand factor (VWF) Description Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic

      Add to Reading List

      Source URL: www.sanquin.nl

      Language: English - Date: 2015-11-10 06:17:54
      7CrossMark_Color_flat+click

      CrossMark_Color_flat+click

      Add to Reading List

      Source URL: www.biophysik.physik.uni-muenchen.de

      Language: English - Date: 2016-01-25 04:04:04
      8HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AFSTYLA safely and effectively. See full prescribing information for AFSTYLA. ----------------------------DOSAGE FOR

      HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AFSTYLA safely and effectively. See full prescribing information for AFSTYLA. ----------------------------DOSAGE FOR

      Add to Reading List

      Source URL: labeling.cslbehring.com

      Language: English - Date: 2016-05-26 14:29:43
      9Major Therapeutic Products Marketed by CSL Behring Bleeding Disorders Coagulation therapies are used to treat bleeding disorders such as hemophilia, Von Willebrand Disease and more. 

      Major Therapeutic Products Marketed by CSL Behring Bleeding Disorders Coagulation therapies are used to treat bleeding disorders such as hemophilia, Von Willebrand Disease and more. 

      Add to Reading List

      Source URL: www.cslbehring.com

      Language: English - Date: 2016-03-15 19:08:23
        10UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows  Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A •

        UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A •

        Add to Reading List

        Source URL: www.nektar.com

        Language: English - Date: 2015-07-30 13:12:07